Literature DB >> 25196952

Rho-kinase as a therapeutic target in vascular diseases: striking nitric oxide signaling.

Gopi Krishna Kolluru1, Syamantak Majumder2, Suvro Chatterjee3.   

Abstract

Rho GTPases are a globular, monomeric group of small signaling G-protein molecules. Rho-associated protein kinase/Rho-kinase (ROCK) is a downstream effector protein of the Rho GTPase. Rho-kinases are the potential therapeutic targets in the treatment of cardiovascular diseases. Here, we have primarily discussed the intriguing roles of ROCK in cardiovascular health in relation to nitric oxide signaling. Further, we highlighted the biphasic effects of Y-27632, a ROCK inhibitor under shear stress, which acts as an agonist of nitric oxide production in endothelial cells. The biphasic effects of this inhibitor raised the question of safety of the drug usage in treating cardiovascular diseases.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Nitric oxide; ROCK inhibitors; Rho-GTPases; Shear stress

Mesh:

Substances:

Year:  2014        PMID: 25196952     DOI: 10.1016/j.niox.2014.09.002

Source DB:  PubMed          Journal:  Nitric Oxide        ISSN: 1089-8603            Impact factor:   4.427


  13 in total

1.  Rho kinase inhibitors: potentially versatile therapy for the treatment of cardiovascular diseases and more.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2015-02-26       Impact factor: 4.345

Review 2.  Rho kinase as a target for cerebral vascular disorders.

Authors:  Lisa M Bond; James R Sellers; Lisa McKerracher
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

Review 3.  Vascular Endothelial (VE)-Cadherin, Endothelial Adherens Junctions, and Vascular Disease.

Authors:  Maria Grazia Lampugnani; Elisabetta Dejana; Costanza Giampietro
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-10-01       Impact factor: 10.005

Review 4.  AT1 receptor signaling pathways in the cardiovascular system.

Authors:  Tatsuo Kawai; Steven J Forrester; Shannon O'Brien; Ariele Baggett; Victor Rizzo; Satoru Eguchi
Journal:  Pharmacol Res       Date:  2017-05-17       Impact factor: 7.658

Review 5.  Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research.

Authors:  Ponugoti Vasantha Rao; Padmanabhan P Pattabiraman; Casey Kopczynski
Journal:  Exp Eye Res       Date:  2016-09-01       Impact factor: 3.467

6.  Interventional Transcatheter Closure Ameliorates the Leukocyte Rho Kinase Activities among Patients with Patent Ductus Arteriosus.

Authors:  Min-Ling Hsieh; Ping-Yen Liu; Jing-Ming Wu; James K Liao; Jieh-Neng Wang
Journal:  Acta Cardiol Sin       Date:  2015-11       Impact factor: 2.672

7.  Chemo-informatics guided study of natural inhibitors targeting rho GTPase: a lead for treatment of glaucoma.

Authors:  Sumit Kumar Rai; Rajesh Kumar Pathak; Dev Bukhsh Singh; Arun Bhatt; Mamta Baunthiyal
Journal:  In Silico Pharmacol       Date:  2021-01-03

8.  Lycopene Ameliorates Transplant Arteriosclerosis in Vascular Allograft Transplantation by Regulating the NO/cGMP Pathways and Rho-Associated Kinases Expression.

Authors:  Yunqiang He; Peng Xia; Hao Jin; Yan Zhang; Bicheng Chen; Ziqiang Xu
Journal:  Oxid Med Cell Longev       Date:  2016-12-05       Impact factor: 6.543

Review 9.  Research advances in kinase enzymes and inhibitors for cardiovascular disease treatment.

Authors:  Rand Shahin; Omar Shaheen; Faris El-Dahiyat; Maha Habash; Sana Saffour
Journal:  Future Sci OA       Date:  2017-08-08

10.  Y-27632 Increases Sensitivity of PANC-1 Cells to EGCG in Regulating Cell Proliferation and Migration.

Authors:  Xing Liu; Yongyi Bi
Journal:  Med Sci Monit       Date:  2016-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.